- Home
- MGTX vs AGMB Comparison
MGTX vs AGMB Comparison
Compare MGTX & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | AGMB |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.1M | 677.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGTX | AGMB |
|---|---|---|
| Price | $9.39 | $10.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $22.86 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 593.3K | 148.1K |
| Earning Date | 05-12-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,391,000.00 | N/A |
| Revenue This Year | $118.35 | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $4.93 | $9.63 |
| 52 Week High | $9.88 | $17.45 |
Technical Indicators
Market Signals| Indicator | MGTX | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 36.77 |
| Support Level | $7.03 | N/A |
| Resistance Level | N/A | $12.81 |
| Average True Range (ATR) | 0.55 | 1.68 |
| MACD | 0.21 | -0.09 |
| Stochastic Oscillator | 82.57 | 7.30 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.